DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

FDL176

Phase One

Phase One

Therapeutic Approach

Restore CFTR Function

FDL176 is a new CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.

Status

Cystic fibrosis transmembrane conductance regulator stimulant in Phase 1

Sponsor

Flatley Discovery Lab

Contact us about FDL176 >